EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis

Anja Gaeckler, Imad Al-Dakkak, Nuria Saval, Hans Herman Dieperink, Margriet Eygenraam, Larry A Greenbaum, Nicole Isbel, Johan Vande Walle

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70278 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Anja Gaeckler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Atypical Hemolytic Uremic Syndrome, Kidney Transplantation, Complement Inactivating Agents. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Boston, MA, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation that may lead to kidney failure. Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of aHUS. This study assessed the real‐world effectiveness and safety of switching to ravulizumab from eculizumab in kidney transplant recipients with aHUS.

Methods

The Global aHUS Registry is a multicenter study enrolling patients with aHUS since 2012. Effectiveness and safety outcomes were assessed in kidney transplant recipients with aHUS who switched to ravulizumab from eculizumab up to September 2, 2024.

Results

Overall, 38 patients received a kidney transplant before ravulizumab initiation; 27 patients with ≥3 months of ravulizumab treatment were included in the patient characteristics and effectiveness analyses. Median (range) time on eculizumab and ravulizumab treatment was 66.1 (3.7, 158.3) and 24.1 (4.2, 49.3) months, respectively ( n = 27); time from last kidney transplantation to ravulizumab initiation was 65.9 (3.7, 184.0) months. Following ravulizumab initiation, laboratory parameters remained stable, and no kidney transplant rejections/graft failures were reported. In the safety analysis ( n = 38), 23 adverse events were reported in 19 patients (50.0%) at or after ravulizumab initiation, and none were considered treatment‐related. No new events of thrombotic microangiopathy or kidney impairment and no meningococcal infections or deaths were reported.

Conclusion

This analysis from the Global aHUS Registry provides real‐world evidence to demonstrate that the transition to ravulizumab from eculizumab in kidney transplant recipients with aHUS is successful, with stable graft function with no treatment‐related safety concerns. Trial Registration ClinicalTrials.gov identifier: NCT01522183

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAtypical Hemolytic Uremic SyndromeKidney TransplantationComplement Inactivating AgentsDrug SubstitutionGraft RejectionKidney Failure, ChronicHumansFemaleMaleRegistriesMiddle AgedPrognosisFollow-Up StudiesAdultGraft SurvivalRisk FactorsAgedGlomerular Filtration RateTransplant Recipients

Stichwörter der Autor:innen

atypical hemolytic uremic syndromecomplementglobal aHUS registrykidney transplantationravulizumabreal‐world datathrombotic microangiopathy

Substanzen

Antibodies, Monoclonal, HumanizedeculizumabravulizumabComplement Inactivating Agents

Autor:innen und Institutionen

  • Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Global Medical Affairs, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
  • Department of Nephrology, Odense University Hospital, Odense, Denmark.
  • aHUS Canada, Brampton, Ontario, Canada.
  • Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Department of Kidney and Transplant Services, The University of Queensland and Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Förderung

  • Alexion, AstraZeneca Rare Disease, Boston, MA, USA

Zitieren

APA

Gaeckler, A., Al-Dakkak, I., Saval, N., Dieperink, H. H., Eygenraam, M., Greenbaum, L. A., Isbel, N., & Walle, J. V. (2025). Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis. Clinical Transplantation. https://doi.org/10.1111/ctr.70278

Vancouver

Gaeckler A, Al-Dakkak I, Saval N, Dieperink HH, Eygenraam M, Greenbaum LA, et al. Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis. Clinical Transplantation. 2025. doi:10.1111/ctr.70278

BibTeX
@article{Gaeckler2025,
  author = {Gaeckler, Anja and Al-Dakkak, Imad and Saval, Nuria and Dieperink, Hans Herman and Eygenraam, Margriet and Greenbaum, Larry A and Isbel, Nicole and Walle, Johan Vande},
  title = {Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70278}
}
Kostenlos starten →